NCT02494258 2026-04-02
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
Celgene
Phase 2 Completed
Celgene
Bristol-Myers Squibb
Bristol-Myers Squibb
Memorial Sloan Kettering Cancer Center
Celgene